New drug combo shows promise for rare thymic cancer
NCT ID NCT03463460
First seen Apr 23, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This study tested a combination of two drugs, pembrolizumab and sunitinib, in 9 people with advanced thymic carcinoma that had spread or couldn't be removed and had stopped responding to standard chemotherapy. The goal was to see if the combination could shrink tumors. The approach uses the immune system and blocks cancer growth signals to try to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYMIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Indiana University
Indianapolis, Indiana, 46202, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.